Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Analyst says Immunogen's T-DM1 will become standard breast cancer treatment; rates stock 'Buy'
Analyst says Immunogen's T-DM1 will become standard breast cancer treatment; rates stock 'Buy'
Analyst says Immunogen's T-DM1 will become standard breast cancer treatment; rates stock 'Buy'
Submitted by
admin
on July 6, 2011 - 8:47am
Source:
Yahoo/AP
News Tags:
Immunogen
T-DM1
breast cancer
Headline:
Analyst says Immunogen's T-DM1 will become standard breast cancer treatment; rates stock 'Buy'
Do Not Allow Advertisers to Use My Personal information
